Abstract

Selective laser trabeculoplasty (SLT) is a glaucoma treatment that reduces intraocular pressure (IOP). Its mechanism is based on the biological effects of the selective application of laser energy to pigmented trabecular meshwork (TM) cells, resulting in increased outflow facility. Herein, we review current publications on SLT and summarize its efficacy and safety for different indications in open-angle glaucoma (OAG) and ocular hypertension (OHT) treatment. SLT effectively reduces IOP when used as a primary treatment. In patients whose IOP is medically controlled, SLT helps to reduce medication use, and when maximally tolerated topical therapy is ineffective, SLT facilitates the realization of the target IOP. SLT is a repeatable procedure for which the vast majority of complications are mild and self-limiting. With effective IOP reduction, low complication rates and the potential to repeat the procedure, SLT offers the possibility of delaying the introduction of medical therapy and other more invasive treatment modalities while simultaneously avoiding the accompanying complications. With this knowledge, we suggest that SLT be considered as an essential primary treatment option in OAG and OHT, switching to other treatment modalities only when laser procedures are insufficient for achieving the required target IOP.

Highlights

  • Intraocular pressure (IOP) is the only modifiable risk factor in the development and progression of glaucomatous optic neuropathy [1,2]

  • The aim of this paper is to summarize key clinical points associated with different indications of Selective laser trabeculoplasty (SLT) used in ocular hypertension (OHT) and open-angle glaucoma (OAG) patients

  • The efficacy of SLT in OAG and OHT treatment has been evaluated in a number of trials, which can be divided in accordance with the indications for which the SLT was used

Read more

Summary

Introduction

Intraocular pressure (IOP) is the only modifiable risk factor in the development and progression of glaucomatous optic neuropathy [1,2]. Decreasing IOP is a fundamental objective of glaucoma treatment. In addition to pharmacotherapy and incisional surgery, laser therapy has been widely used in glaucoma treatment for many years. In 1995, Latina and Park introduced SLT and proved that laser treatment could be applied selectively to pigmented trabecular meshwork (TM) cells [3]. In contrast to argon laser trabeculoplasty (ALT), the previous standard treatment, SLT avoids thermal damage to adjacent non-pigmented structures [4]. The Food and Drug Agency (FDA) approved the procedure in 2002, and since that time, it has become a widely used treatment option as both a primary and adjunctive treatment for most types of glaucoma. We suggest that SLT be considered as an important treatment option at different stages of glaucoma

Objectives
Methods
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call